Investors might want to bet on Takeda Pharmaceutical Co. (TAK), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Thank you very much for taking time out of their busy schedule to join our earnings announcement for FY '24 for Takeda. I'm the master of ceremony, Head of IR. My name is O'Reilly. Thank you for ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a potential "inflection point" for the company. President Donald Trump is ...

NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts.

Fantasy light novels and manga are usually power fantasies for their target audience, especially when it's male, so the main tenet of the "old guy with serious skills" story is about being older ...

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch ...

One company to watch right now is Takeda Pharmaceutical Co. (TAK). TAK is currently sporting a Zacks Rank of #1 (Strong Buy), as well as an A grade for Value. Another notable valuation metric for ...

Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, but can now celebrate a vestry after getting FDA approval for first-in-class lung cancer therapy Exkivity.

Takeda is to acquire TiGenix, the stem cell specialist biotech with which it has developed a gastro stem cell therapy, in a deal worth 520 million euros ($626 million). The decision follows ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: May 9 at 4:00:02 PM EDT ...